sulfasalazine has been researched along with Breast Neoplasms in 12 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to clarify the activation of ferroptosis in different breast cancer cells by sulfasalazine (SAS) and to explore the relationship between the estrogen receptor (ER) and the transferrin receptor (TFRC)." | 7.91 | Sulfasalazine‑induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor. ( Chen, R; Fu, Y; Guo, S; Jian, L; Li, K; Liu, S; Luo, F; Qu, F; Tao, K; Yang, C; Yu, H, 2019) |
| " Immunodeficient mice were inoculated intrafemorally with the human breast adenocarcinoma cell line MDA-MB-231, then treated 14days later via mini-osmotic pumps inserted intraperitoneally with sulfasalazine, (S)-4-carboxyphenylglycine, or vehicle." | 7.80 | Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain. ( Seidlitz, EP; Singh, G; Ungard, RG, 2014) |
| " Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors." | 5.48 | Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys. ( Abe, K; Ando, O; Imaoka, T; Karibe, T, 2018) |
| "Incubation of the mammary cancer cells with SASP (0." | 5.34 | Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. ( Buckley, AR; Buckley, DJ; Gout, PW; Narang, VS; Pauletti, GM, 2007) |
| " Here, we examined the effect of hypoxia in cysteine-deprived breast cancer cells and the mechanism to counteract the hypoxia effect." | 3.96 | Hypoxia Suppresses Cysteine Deprivation-induced Cell Death ( Hong, SE; Jang, SK; Jin, HO; Kim, HA; Kim, MR; Noh, WC; Park, IC; Seong, MK, 2020) |
| "The aim of the present study was to clarify the activation of ferroptosis in different breast cancer cells by sulfasalazine (SAS) and to explore the relationship between the estrogen receptor (ER) and the transferrin receptor (TFRC)." | 3.91 | Sulfasalazine‑induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor. ( Chen, R; Fu, Y; Guo, S; Jian, L; Li, K; Liu, S; Luo, F; Qu, F; Tao, K; Yang, C; Yu, H, 2019) |
| " Immunodeficient mice were inoculated intrafemorally with the human breast adenocarcinoma cell line MDA-MB-231, then treated 14days later via mini-osmotic pumps inserted intraperitoneally with sulfasalazine, (S)-4-carboxyphenylglycine, or vehicle." | 3.80 | Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain. ( Seidlitz, EP; Singh, G; Ungard, RG, 2014) |
| "Among the 48 human ABC proteins, the breast cancer resistance protein (BCRP/ABCG2) has been described as a pivotal player in cancer resistance." | 2.82 | Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. ( Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF, 2022) |
| "In this study, we found that breast cancer cells with a high expression of xCT demonstrated increased levels of reactive oxygen species (ROS) and were more sensitive to glucose deprivation than the cells with a low expression of xCT." | 1.56 | ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation. ( Chen, MC; Hsu, CY; Hsu, LL; Lee, HC; Tseng, LM; Wang, SF, 2020) |
| " Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors." | 1.48 | Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys. ( Abe, K; Ando, O; Imaoka, T; Karibe, T, 2018) |
| "In sum, we demonstrate how breast cancer bone metastases upregulate a cystine/glutamate co-transporter to elevate extracellular glutamate." | 1.43 | The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain. ( BassiriRad, NM; Bui, L; Doyle, T; Forte, BL; Largent-Milnes, TM; Mantyh, PW; Neumann, WL; Salvemini, D; Slosky, LM; Staatz, WD; Symons, AM; Thompson, M; Vanderah, TW, 2016) |
| "Incubation of the mammary cancer cells with SASP (0." | 1.34 | Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. ( Buckley, AR; Buckley, DJ; Gout, PW; Narang, VS; Pauletti, GM, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zattoni, IF | 1 |
| Delabio, LC | 1 |
| Dutra, JP | 1 |
| Kita, DH | 1 |
| Scheiffer, G | 1 |
| Hembecker, M | 1 |
| Pereira, GDS | 1 |
| Moure, VR | 1 |
| Valdameri, G | 1 |
| Usukhbayar, N | 1 |
| Uesugi, S | 1 |
| Kimura, KI | 1 |
| Eyre, R | 1 |
| Alférez, DG | 1 |
| Santiago-Gómez, A | 1 |
| Spence, K | 1 |
| McConnell, JC | 1 |
| Hart, C | 1 |
| Simões, BM | 1 |
| Lefley, D | 1 |
| Tulotta, C | 1 |
| Storer, J | 1 |
| Gurney, A | 1 |
| Clarke, N | 1 |
| Brown, M | 1 |
| Howell, SJ | 1 |
| Sims, AH | 1 |
| Farnie, G | 1 |
| Ottewell, PD | 1 |
| Clarke, RB | 1 |
| Hong, SE | 1 |
| Kim, MR | 1 |
| Jang, SK | 1 |
| Seong, MK | 1 |
| Kim, HA | 1 |
| Noh, WC | 1 |
| Jin, HO | 1 |
| Park, IC | 1 |
| Chen, MC | 1 |
| Hsu, LL | 1 |
| Wang, SF | 1 |
| Hsu, CY | 1 |
| Lee, HC | 1 |
| Tseng, LM | 1 |
| Tanabe, A | 1 |
| Kimura, K | 1 |
| Tazawa, H | 1 |
| Maruo, T | 1 |
| Taguchi, M | 1 |
| Sahara, H | 1 |
| Liao, M | 1 |
| Chuang, BC | 1 |
| Zhu, Q | 1 |
| Li, Y | 1 |
| Guan, E | 1 |
| Yu, S | 1 |
| Yang, J | 1 |
| Prakash, S | 1 |
| Xia, CQ | 1 |
| Karibe, T | 1 |
| Imaoka, T | 1 |
| Abe, K | 1 |
| Ando, O | 1 |
| Yu, H | 1 |
| Yang, C | 1 |
| Jian, L | 1 |
| Guo, S | 1 |
| Chen, R | 1 |
| Li, K | 1 |
| Qu, F | 1 |
| Tao, K | 1 |
| Fu, Y | 1 |
| Luo, F | 1 |
| Liu, S | 1 |
| Ungard, RG | 1 |
| Seidlitz, EP | 1 |
| Singh, G | 1 |
| Slosky, LM | 1 |
| BassiriRad, NM | 1 |
| Symons, AM | 1 |
| Thompson, M | 1 |
| Doyle, T | 1 |
| Forte, BL | 1 |
| Staatz, WD | 1 |
| Bui, L | 1 |
| Neumann, WL | 1 |
| Mantyh, PW | 1 |
| Salvemini, D | 1 |
| Largent-Milnes, TM | 1 |
| Vanderah, TW | 1 |
| Narang, VS | 1 |
| Pauletti, GM | 1 |
| Gout, PW | 1 |
| Buckley, DJ | 1 |
| Buckley, AR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Methadone for 'Adenocarcinopathic' Pain Treatment: Methadone vs. Morphine Vanguard RCT[NCT05325164] | Phase 3 | 0 participants (Actual) | Interventional | 2022-09-30 | Withdrawn (stopped due to Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.) | ||
| Clinical Study Evaluating the Efficacy and Safety of Sulfasalazine in Patients With Metastatic Colorectal Cancer[NCT06134388] | Phase 3 | 50 participants (Anticipated) | Interventional | 2023-09-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sulfasalazine and Breast Neoplasms
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Dr | 2022 |
11 other studies available for sulfasalazine and Breast Neoplasms
| Article | Year |
|---|---|
3,6-Epidioxy-1,10-bisaboladiene and sulfasalazine synergistically induce ferroptosis-like cell death in human breast cancer cell lines.
Topics: Anti-Inflammatory Agents; Breast Neoplasms; Cell Death; Female; Ferroptosis; HL-60 Cells; Humans; Su | 2023 |
Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cell Line | 2019 |
Hypoxia Suppresses Cysteine Deprivation-induced Cell Death
Topics: Activating Transcription Factor 4; Breast Neoplasms; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cys | 2020 |
ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
Topics: Acetylcysteine; Amino Acid Transport System y+; AMP-Activated Protein Kinase Kinases; Antineoplastic | 2020 |
Functional analysis of CD44 variants and xCT in canine tumours.
Topics: Amino Acid Transport Systems, Acidic; Animals; Biomarkers, Tumor; Breast Neoplasms; Dog Diseases; Do | 2021 |
Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).
Topics: Absorption, Physiological; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast | 2018 |
Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; ATP Binding Cassette Transporter, Subfamily B, Mem | 2018 |
Sulfasalazine‑induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Apoptosis; Biomarkers, Tumor; Breast Neoplasm | 2019 |
Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoates; Bone and Bones; Breast | 2014 |
The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiporters; Bone Neoplasms; Breas | 2016 |
Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti | 2007 |